The European Union (EU) is the second largest pharma market in the world and represents a major opportunity for U.S. biotechnology companies. Due to the perceived complexity of launching in Europe, many biotech companies licence their products to partner companies. Often as a result, the full value of the product is not realised by the parent company.
With a greater understanding of the EU region, companies can make more informed choices, secure better deal terms with partners and explore alternative commercialization options.
European Commercialization Key Business Questions
Download the full article for an in-depth view of executing a pan-European commercialization strategy:
As the lead for EVERSANA’s EMEA management consulting practice, Ed specializes in commercial and corporate strategy and has significant national and global launch experience. He has helped a diverse set of clients from big…